1092447-71-6 Usage
Ethyl ester derivative
2-amino-5,6-difluoro-indan-2-carboxylic acid The compound is derived from 2-amino-5,6-difluoro-indan-2-carboxylic acid by attaching an ethyl ester group.
Fluorinated indan
Indan-2-carboxylic acid The compound is a fluorinated derivative of indan-2-carboxylic acid, which adds unique properties to the molecule.
Building block in pharmaceutical synthesis
The compound is commonly used as a building block in the synthesis of pharmaceutical compounds, making it a valuable intermediate for drug development.
Potential applications in anticancer and antiviral agents
Due to its unique structure and fluorinated substituents, the compound has potential applications in the development of anticancer and antiviral drugs.
Value in chemical research and development
The compound may have potential applications in other areas of chemical research and development, thanks to its unique chemical and pharmacological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1092447-71-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,4,4 and 7 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1092447-71:
(9*1)+(8*0)+(7*9)+(6*2)+(5*4)+(4*4)+(3*7)+(2*7)+(1*1)=156
156 % 10 = 6
So 1092447-71-6 is a valid CAS Registry Number.
1092447-71-6Relevant articles and documents
SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS
-
Page/Page column 107-108, (2009/01/24)
The present invention relates to A compound of the formula Ia wherein in any of its stereoisomers forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.
